SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 84 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,170 | +53.4% | 218,300 | +168.8% | 0.01% | +66.7% |
| Q4 2022 | $2,067 | -99.9% | 81,200 | -55.4% | 0.00% | -25.0% |
| Q1 2022 | $3,165,000 | +125.6% | 182,100 | +92.3% | 0.00% | +300.0% |
| Q2 2020 | $1,403,000 | -73.8% | 94,700 | -80.6% | 0.00% | -80.0% |
| Q1 2020 | $5,349,000 | +23.0% | 487,600 | -1.6% | 0.01% | +66.7% |
| Q4 2019 | $4,350,000 | +17.2% | 495,500 | -0.3% | 0.00% | 0.0% |
| Q3 2019 | $3,713,000 | -7.7% | 497,000 | +15.1% | 0.00% | -25.0% |
| Q2 2019 | $4,021,000 | +143.4% | 431,900 | +37.3% | 0.00% | +100.0% |
| Q1 2019 | $1,652,000 | +62.1% | 314,600 | +37.3% | 0.00% | +100.0% |
| Q4 2018 | $1,019,000 | -54.9% | 229,100 | -18.0% | 0.00% | -50.0% |
| Q3 2018 | $2,257,000 | +116.2% | 279,300 | +194.6% | 0.00% | +100.0% |
| Q2 2018 | $1,044,000 | +39.8% | 94,800 | +80.6% | 0.00% | 0.0% |
| Q1 2018 | $747,000 | +232.0% | 52,500 | +104.3% | 0.00% | – |
| Q4 2017 | $225,000 | – | 25,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |